戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ebellar syndrome, which in 45% occurred with opsoclonus.
2 lonus, tongue and orofacial dyskinesias, and opsoclonus.
3                              The presence of opsoclonus, ataxia, and chorea expands the clinical phen
4 ho presented with a mixed movement disorder (opsoclonus, ataxia, and chorea) as well as seizures refr
5 nt who presented with acute-onset confusion, opsoclonus, chorea, and intractable seizures.
6 s, a favorable prognosis was associated with opsoclonus, female sex, and diagnosis before 12 months o
7 nd associated with a poor prognosis, whereas opsoclonus, female sex, and younger age at diagnosis wer
8 ings were orbital involvement in 37 (43.0%), opsoclonus in 20 (23.3%), and Horner syndrome in 24 (27.
9 ub-acute syndromes (transverse myelitis (1), opsoclonus myoclonus (1)).
10 cute syndromes (transverse myelitis [n = 1], opsoclonus myoclonus [n = 1]).
11                               Paraneoplastic opsoclonus myoclonus ataxia (POMA) is a neurologic disor
12 at is an autoimmune target in paraneoplastic opsoclonus myoclonus ataxia (POMA) patients with latent
13     Nova-1, an autoantigen in paraneoplastic opsoclonus myoclonus ataxia (POMA), a disorder associate
14 specific antigens targeted in paraneoplastic opsoclonus myoclonus ataxia (POMA), an autoimmune neurol
15    In patients suffering from paraneoplastic opsoclonus myoclonus ataxia (POMA), Nova-1 and Nova-2 pr
16  2 with meningoencephalomyelitis, and 1 with opsoclonus myoclonus syndrome.
17 nces and its association with paraneoplastic opsoclonus, myoclonus, and ataxia.
18 requency, were brainstem syndrome (including opsoclonus, myoclonus, or both), cerebellar syndrome, my
19         Despite circumstantial evidence that opsoclonus-myoclonus (OM) is often immune mediated, no s
20 A-binding protein Nova-1, the paraneoplastic opsoclonus-myoclonus ataxia (POMA) antigen.
21 red neurologic condition, the paraneoplastic opsoclonus-myoclonus ataxia (POMA).
22  with the autoimmune disorder paraneoplastic opsoclonus-myoclonus ataxia (POMA).
23 araneoplastic motor disorder [paraneoplastic opsoclonus-myoclonus ataxia (POMA)].
24 ns in the autoimmune disorder paraneoplastic opsoclonus-myoclonus ataxia and contain K-homology (KH)-
25 nditions, with the possible exception of the opsoclonus-myoclonus ataxia and Lambert-Eaton myasthenic
26  with the autoimmune disorder paraneoplastic opsoclonus-myoclonus ataxia, which is characterized by f
27 neurological symptoms, termed paraneoplastic opsoclonus-myoclonus ataxia.
28     Syndromes such as limbic encephalitis or opsoclonus-myoclonus should always raise suspicion of a
29                              Most studies on opsoclonus-myoclonus syndrome (OMS) in adults are based
30 araneoplastic cerebellar degeneration, and 1 opsoclonus-myoclonus syndrome).
31 echnique in 2 patients recovering from viral opsoclonus-myoclonus syndrome, comparing saccadic-vergen
32 g on paraneoplastic cerebellar degeneration, opsoclonus-myoclonus, and encephalitides affecting the l
33 icated in the pathogenesis of paraneoplastic opsoclonus-myoclonus-ataxia (POMA).
34                                              Opsoclonus-myoclonus-ataxia syndrome (OMS) is a severe a
35 eizures and limbic involvement), and two had opsoclonus-myoclonus.
36 ies), neuromyotonia (Caspr2 antibodies), and opsoclonus--myoclonus--ataxia (unknown antigens).
37  uncover a novel phenotype of paraneoplastic opsoclonus that until recently was likely considered idi